Wave Life Sciences/$WVE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Wave Life Sciences

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Ticker

$WVE
Sector
Health
Primary listing
NASDAQ

Employees

288

Headquarters

Singapore, Singapore
Website
wavelifesciences.com

WVE Metrics

BasicAdvanced
$1.3B
-
-$0.84
-1.02
-

What the Analysts think about WVE

Analyst ratings (Buy, Hold, Sell) for Wave Life Sciences stock.

Bulls say / Bears say

Wave’s stock jumped 51% after the March 2025 Phase 2 FORWARD-53 trial of WVE-N531 in Duchenne muscular dystrophy delivered a 3.8-second improvement in Time-to-Rise and reversal of muscle fibrosis at 48 weeks.
WVE-006, the GalNAc-RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, completed multidose testing in the 200 mg group and a single dose in the 400 mg group in the RestorAATion-2 trial, highlighting swift clinical progress.
Wave had $208.5 million in cash as of June 30, 2025, giving funding runway into 2027 for its RNA medicines pipeline without a need for immediate new financing.
Wave reported a net loss of $46.9 million in Q1 2025, up from $31.6 million in the previous year, due to much higher R&D and administrative expenses.
Cash and cash equivalents fell from $302.1 million as of December 31, 2024 to $243.1 million at March 31, 2025, showing a high cash burn as clinical activity increased.
Major data releases for WVE-007 in obesity are not expected before the second half of 2025, and the IND submission for WVE-003 in Huntington’s disease is expected only in late 2025, pushing out key potential catalysts.
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.

WVE Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

WVE Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

WVE News

AllArticlesVideos
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?

Benzinga2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $WVE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs